Regorafenib
Colorectal Neoplasm
Sergey Orlov, MDSmall moleculePhase 4 / ApprovedActive
BB
71/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 70/ 100
- Competitive Position
- 73/ 100
Competitive context
116 Active assets in the Colorectal Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Xaliplatin Peking University Cancer Hospital & Institute | Phase 4 | BBB |
FLUOROURACILUM Rutgers, The State University of New Jersey | Phase 4 | BBB |
Irinotecan Shanghai Zhongshan Hospital | Phase 4 | BBB |
Ferric Carboxymaltose [Ferinject] Nottingham University Hospitals NHS Trust | Phase 4 | BBB |
Capecitabine Rutgers, The State University of New Jersey | Phase 4 | BB |
View all 49 →
Same molecule, other indications
Regorafenib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →